Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties
May 02, 2022 06:50 ET
|
Bright Minds Biosciences
-- Herbert Y. Meltzer, MD; Karl Deisseroth, MD, PhD; Robert C. Malenka, MD, PhD; Michael P. Bogenschutz, MD; and Peter Hendricks, PhD, bring decades of clinical and research expertise in psychiatry,...
Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders
April 19, 2022 06:50 ET
|
Bright Minds Biosciences
-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) --...
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
March 14, 2022 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference
March 08, 2022 07:30 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference
January 04, 2022 16:05 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference
December 06, 2021 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases
November 30, 2021 07:30 ET
|
Bright Minds Biosciences
— Hundreds of de novo patentable psychedelic-based compounds created through discovery program — — Company plans to announce lead molecule in first quarter of 2022 — VANCOUVER, British Columbia,...
Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”
November 03, 2021 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference
October 06, 2021 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on...
Bright Minds Biosciences Provides Scientific Update
September 22, 2021 07:00 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on...